158 filings
Page 2 of 8
8-K
1ef44sq15uqmk17c f0
2 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
hk0t9eu8mtge2n1s9ky
8 May 23
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
4:03pm
ARS
flhl5un6bz
18 Apr 23
Annual report to shareholders
4:05pm
DEFA14A
snvdki9
18 Apr 23
Additional proxy soliciting materials
4:04pm
S-8
0poh9qs 9qv
27 Feb 23
Registration of securities for employees
4:08pm
8-K
xq1rjq0jfjd
27 Feb 23
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
4:04pm
8-K
x01ny
9 Jan 23
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
8:08am
8-K
uedvi004hhf853pjj9
3 Nov 22
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
4:05pm
8-K
9mww 4fp91w4wxcyelka
20 Oct 22
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
4:58pm
424B5
nl4p9 8e717uein67
20 Oct 22
Prospectus supplement for primary offering
4:57pm
8-K
3knmg 2tl3
18 Oct 22
Denali Therapeutics Announces Proposed Offering of Common Stock
5:09pm
424B5
s5j9xlgmcmwb383sszig
18 Oct 22
Prospectus supplement for primary offering
5:08pm
8-K
sp7y7sgb
8 Aug 22
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
4:03pm
8-K
849dd2
5 Jul 22
Regulation FD Disclosure
8:01am
8-K
xeks4
3 Jun 22
Submission of Matters to a Vote of Security Holders
4:01pm